Moderna, Inc. (MRNA) stock plummeted 6.26% on Monday during intraday trading, following the company's disappointing international revenue performance in the fourth quarter of 2024.
The biotechnology company reported total revenue of $966 million for the quarter, marking a significant 65.6% decline from the prior-year period. While Moderna's revenue from Europe exceeded expectations, contributing $292 million (30.23% of total revenue), its performance in the rest of world markets fell short of analysts' projections.
Revenue from the rest of world region totaled $397 million (41.10% of total revenue), missing Wall Street estimates by 27.97%. This lackluster performance, coupled with analysts' projections of further revenue declines in 2025, likely contributed to Moderna's stock plunge.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。